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Progressive tissue fibrosis is a major cause of 
morbidity and mortality. Although numerous 
mediators  have  been  identified  as  initiating 
tissue fibrosis, the mechanisms that contribute 
to  persistent  fibrodestructive  disease  remain 
incompletely understood. Fibroblasts are criti­
cal effector cells in mediating tissue remodel­
ing. At sites of tissue injury and remodeling, 
there is also the accumulation of myofibro­
blasts, and their origins remain a source of   
active investigation (Hinz et al., 2007). Myo­
fibroblasts are important sources of matrix pro­
duction and also have contractile properties 
critical for wound healing (Blankesteijn et al., 
1997). One of the defining characteristics of 
myofibroblasts is the expression of –smooth 
muscle actin (ASMA). Intratracheal adminis­
tration of bleomycin has been widely used as a 
model to study the mechanisms of noninfectious 
injury and repair in the lung. Myofibroblasts 
are recruited to the lung interstitium 7–14 d 
after bleomycin injury and dissipate through 
apoptosis by 21 d (Zhang et al., 1996). Although 
considerable evidence has accumulated defin­
ing mediators such as TGF­ that are essential 
for fibroblasts to express ASMA and assume 
contractile functions (Kim et al., 2009), there 
has been no in vivo demonstration that con­
trolling ASMA­expressing cells regulates chronic 
tissue fibrosis.
Idiopathic pulmonary fibrosis (IPF) is a 
terminal illness characterized by progressive 
and unremitting matrix deposition in the inter­
stitium  of  the  lung  (Bjoraker  et  al.,  1998). 
The clinical course of IPF is unrelenting and 
reminiscent of cancer with patients suffocating 
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Tissue fibrosis is a major cause of morbidity, and idiopathic pulmonary fibrosis (IPF) is a 
terminal illness characterized by unremitting matrix deposition in the lung. The mechanisms 
that control progressive fibrosis are unknown. Myofibroblasts accumulate at sites of tissue 
remodeling and produce extracellular matrix components such as collagen and hyaluronan 
(HA) that ultimately compromise organ function. We found that targeted overexpression of 
HAS2 (HA synthase 2) by myofibroblasts produced an aggressive phenotype leading to 
severe lung fibrosis and death after bleomycin-induced injury. Fibroblasts isolated from 
transgenic mice overexpressing HAS2 showed a greater capacity to invade matrix. Condi-
tional deletion of HAS2 in mesenchymal cells abrogated the invasive fibroblast phenotype, 
impeded myofibroblast accumulation, and inhibited the development of lung fibrosis. Both 
the invasive phenotype and the progressive fibrosis were inhibited in the absence of CD44. 
Treatment with a blocking antibody to CD44 reduced lung fibrosis in mice in vivo. Finally, 
fibroblasts isolated from patients with IPF exhibited an invasive phenotype that was also 
dependent on HAS2 and CD44. Understanding the mechanisms leading to an invasive 
fibroblast phenotype could lead to novel approaches to the treatment of disorders charac-
terized by severe tissue fibrosis.
© 2011 Li et al.  This article is distributed under the terms of an Attribution– 
Noncommercial–Share  Alike–No  Mirror  Sites  license  for  the  first  six  months   
after the publication date (see http://www.rupress.org/terms). After six months 
it  is  available  under  a  Creative  Commons  License  (Attribution–Noncommer-
cial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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caused by impaired cardiac development (Camenisch et al., 
2000). CD44 is the major cell surface receptor for HA and 
plays an important role in inflammatory cell recruitment 
(Mikecz et al., 1995; Siegelman et al., 1999) and activation 
(Noble et al., 1993; DeGrendele et al., 1997), as well as   
tumor growth and metastasis (Lesley et al., 1993). We have 
previously  shown  that  CD44  is  necessary  for  hemato­
poietic cells to clear HA from sites of inflammation (Teder   
et al., 2002). CD44 has been shown to be critical for the 
recruitment  of  fibroblasts  to  the  injury  sites  (Acharya   
et al., 2008). The role of CD44 in fibrogenesis has not been 
directly addressed.
The inexorable course of progressive fibrosis in IPF led us 
to postulate that fibroblasts may take on properties similar to 
metastatic cancer cells that overexpress HA. Consistent with 
this concept is a recent study showing that IPF fibroblasts 
have abnormalities in translational control (Larsson et al., 
2008) that can be found in cancer cells. One of the seminal 
properties of metastatic cancer cells is the ability to invade 
basement membrane. We reasoned that fibrotic fibroblasts and 
myofibroblasts drive fibrogenesis by invasion and destruction 
of basement membrane and that HA–CD44 interactions may 
regulate this process. We investigated the hypothesis that   
fibrotic fibroblasts acquire an invasive phenotype that is es­
sential for progressive fibrogenesis and that HA and CD44 
have critical roles in regulating the process.
from the inexorable accumulation of extracellular matrix 
in the gas­exchanging regions of the lung. A hallmark and 
defining pathological feature of IPF is the formation of   
fibroblastic foci, which are the accumulation of myofibro­
blasts  in  the  interstitium  of  the  lung  juxtaposed  to  the 
alveolar epithelium with destruction of the adjoining alve­
olar basement membrane (Selman and Pardo, 2002). The 
destruction of alveolar basement membrane was also ob­
served in experimental lung fibrosis (Fukuda et al., 1985; 
Vaccaro et al., 1985). Fibroblasts and myofibroblasts from 
IPF patients have been shown to have distinct properties 
(Larsson et al., 2008), including the ability to invade extra­
cellular matrix in the manner of metastatic cancer cells 
(White et al., 2003a).
Hyaluronan (HA) is a nonsulfated glycosaminoglycan 
produced by mesenchymal cells and a variety of tumor cells 
and has been suggested to contribute to tumor metastasis 
through interactions with its cognate cell surface receptor 
CD44 (Arch et al., 1992; Toole, 2004). Accumulation of HA 
has been shown to be a characteristic of disorders that are 
associated with progressive tissue fibrosis (Bjermer et al., 
1989). HA has also been shown to accumulate in the lung 
after bleomycin treatment and has a role in regulating the 
inflammatory response (Jiang et al., 2005, 2011). Three HA 
synthase genes (HAS1–3) have been identified. Targeted 
deletion of HAS2 generates an embryonic lethal phenotype 
Figure 1.  ASMA-HAS2 transgenic mice accumulate HA and show increased mortality after bleomycin challenge. (A) Distribution of HA in 
lungs of ASMA-HAS2+ and littermate control mice (ASMA-HAS2) was determined by immunohistochemical staining of HA with biotin-HABP. Represen-
tative sections from five bleomycin-treated samples and three controls are shown. The specificity of the staining was determined by preincubating tissue 
samples with 10 U/ml streptomyces hyaluronidase for 2 h at room temperature (not depicted). Bar, 50 µm. (B and C) HA concentration in lung tissue (B) 
and BALF (C) from ASMA-HAS2+ mice and control mice (ASMA-HAS2) at different times after bleomycin treatment (n = 5–7; *, P < 0.05; **, P < 0.01).  
(D and E) Murine HAS2 (mHAS2; D and E) and human HAS2 (hHAS2; E) mRNA expression levels in ASMA-HAS2+ mice and controls (ASMA-HAS2) at 
various time points after bleomycin treatment were measured using real-time PCR (n = 3–5; **, P < 0.01; ***, P < 0.001). (B–E) Error bars indicate mean ± 
SEM. (F) ASMA-HAS2+ and control mouse lung injury was induced after intratracheal inoculation with the indicated dose of bleomycin. Percentages of 
surviving mice were plotted over a 21-d period (for 1.75 U/kg: n = 8 per group, P = 0.14; for 2.5 U/kg: n = 16 per group, P = 0.05; for 5.0 U/kg: n = 9 per 
group, P < 0.05; red line, ASMA-HAS2; blue line, ASMA-HAS2+). (A–F) Experiments were performed three times.JEM Vol. 208, No. 7 
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We  then  examined  the  fibrotic  response  in ASMA­HAS2 
transgenic mice and found evidence of progressive fibrosis at 
time points (28 d) when the fibrotic response in transgene­
negative mice was abating (Fig. 2, A and B). Both the magni­
tude and duration of the fibrotic response were greater in the 
ASMA­HAS2 transgenic mice. Furthermore, a fibrodestruc­
tive response in the periphery of the lung was observed in the 
ASMA­HAS2 transgenic mice (Fig. 2 A) similar to that ob­
served in lung tissue from patients with IPF. We also found an 
impressive increase in the accumulation of ASMA staining in 
lung tissue from ASMA­HAS2 transgenic mice consistent with 
greater accumulation of myofibroblasts (Fig. 2, C and D), which 
is similar to what is observed in IPF lung tissue (Fig. 2 E).
Conditional knockout of HAS2 in mesenchymal cells 
diminishes the accumulation of myofibroblasts  
and the development of pulmonary fibrosis
HAS2­deficient mice have an embryonic lethal phenotype 
(Camenisch et al., 2000). To ascertain the role of HA in 
mesenchymal cell functions, we generated Has2flox/+ mice 
(Matsumoto et al., 2009) and crossed them with a Col12­iCre 
transgenic line (Florin et al., 2004). Unfortunately, the vast 
majority  of  Col12­iCre+/Has2flox/flox  mice  (Has2CKO/CKO) 
also die in utero, suggesting that HA production by mesen­
chymal cells drives the phenotype. We were able to perform 
bleomycin experiments with nine surviving mice obtained over 
the  years  from  extensive  breeding.  Conditional  Has2CKO/CKO 
mice were treated with bleomycin at 8 wk of age. Our 
preliminary data showed that Has2CKO/CKO mice had mini­
mal HA staining in bronchial tissues at baseline and devel­
oped significantly less fibrosis after lung injury as estimated by 
trichrome  staining 
(Fig. S3, A and B). 
RESULTS
Targeted overexpression of HAS2 in ASMA-expressing cells 
generates a severe fibrotic phenotype
To characterize the role of HAS2 expression by myofibroblasts 
in the pathogenesis of pulmonary fibrosis, we evaluated trans­
genic mice with targeted human HAS2 expression in ASMA­
expressing cells (Chai et al., 2005). ASMA­HAS2 transgenic 
mice develop normally and exhibit no overt phenotype in the 
unchallenged state. Intratracheal administration of bleomycin 
recruits myofibroblasts (Zhang et al., 1996) and causes pulmo­
nary fibrosis. ASMA­HAS2 transgenic mice exhibited an in­
crease in HA deposition around large airways and blood vessels 
at baseline and accumulate increased concentrations of HA in 
both the lung interstitium and alveolar space after injury (Fig. 1, 
A–C). Endogenous murine HAS2 gene expression was up­
regulated after bleomycin treatment (Fig. 1 D), but human 
HAS2 was only expressed in the transgenic mice (Fig. 1 E). 
ASMA­HAS2  transgenic  mice  demonstrated  a  marked  in­
crease in mortality after lung injury over a dose range of 
bleomycin (Fig. 1 F). To evaluate the mechanisms leading to 
increased mortality in ASMA­HAS2 transgenic mice, we first 
examined the inflammatory response after lung injury. ASMA­
HAS2 transgenic mice were found to have an increase in total 
inflammatory cells relative to transgene negative controls, and 
the increase was largely the result of an influx of neutrophils 
(Fig. S1, A–C). We analyzed the bronchoalveolar lavage (BAL) 
fluid (BALF) for neutrophil chemotactic peptides and found a 
significant increase in the chemokine KC in the ASMA­HAS2 
transgenic mice (Fig. S1 D). It has previously been shown that 
HA fragments accumulate after lung injury and stimulate macro­
phages  to  produce  inflammatory  mediators  (McKee  et  al., 
1996). ASMA­HAS2 transgenic mice were found to accumu­
late abundant HA fragments in lung tissue (Fig. S2, A and B). 
Figure 2.  ASMA-HAS2 transgenic mice 
exhibit increased collagen content in 
lungs after bleomycin treatment. (A) Lung 
sections of ASMA-HAS2+ and transgene nega-
tive controls 0, 14, and 28 d after bleomycin 
instillation were stained using Masson’s tri-
chrome method. Representative images of the 
staining are shown (n = 6–7). (B) Lung tissues 
from ASMA-HAS2+ and controls on days 0, 
14, 21, and 28 after bleomycin treatment were 
collected and assayed for collagen content 
using the hydroxyproline method (n = 6–7 per 
group; *, P < 0.05; ****, P < 0.0001). The ex-
periments were performed three times. Error 
bars indicate mean ± SEM. (C and D) Immuno-
histochemical (C) and immunofluorescent 
analysis (D) of ASMA and HA in lung sections 
of ASMA-HAS2+ and control mice 14 d after 
bleomycin treatment. Representative images 
of the staining are shown (n = 6–7). (C) DAB 
staining is shown. (D) Immunofluorescence 
staining is shown. (E) Representative images 
of IPF patients’ and control lung tissues 
showing ASMA staining and similar fibrotic 
changes to bleomycin-induced lung fibrosis. 
Bars: (A and E) 200 µm; (C and D) 50 µm.1462 Matrix regulates fibroblast invasion | Li et al.
and that HAS2 is critical in regulating the process. We used an 
assay system in which fibroblasts are evaluated for their ability 
to spontaneously invade Matrigel, a composite matrix with 
basement membrane constituents. This assay has been used to 
analyze the metastatic potential of cancer cells (Qian et al., 
1994; Karnoub et al., 2007). We compared fibroblasts isolated 
from ASMA­HAS2 transgenic mice and littermate control 
mice before and after bleomycin challenge. We found that   
fibrotic fibroblasts spontaneously invaded Matrigel (Fig. 4 A). 
Interestingly, invasive fibroblasts demonstrated increased HAS2 
messenger RNA (mRNA) expression relative to fibroblasts 
isolated that did not invade matrix (Fig. 4 B), suggesting that 
Has2 expression is an important feature of the subset of   
fibroblasts that invade matrix. Fibroblasts isolated from bleo­
mycin­treated ASMA­HAS2 transgenic mice demonstrated 
greater invasive capacity than transgene­negative controls 
(Fig. 4 A). To determine the contribution of HA to the inva­
sive phenotype, we sought to identify fibroblasts deficient in 
HAS2 expression and HA production. We were able to isolate 
fibroblasts from Has2CKO/CKO and Has2FKO/FKO mice and ex­
amined HA production. A hallmark of mesenchymal cell HA 
expression is the formation of cell surface HA coats (Spicer et al., 
1996). HA is synthesized in the cell membrane and extruded 
to the external milieu (Itano et al., 1999). Conditional Has2­
null (Has2CKO/CKO) fibroblasts showed a marked reduction in 
In addition, at sites of lung remodeling, there was a marked 
reduction in myofibroblast accumulation in the lung relative 
to WT or ASMA­HA transgenic mice (Fig. S3 C). To further 
assess the contribution of fibroblast expression of HAS2, we 
used an additional Cre line using the FSP­1 promoter. FSP­1 
is expressed by lung fibroblasts (Lawson et al., 2005; Tanjore   
et al., 2009). FSP­1–Cre mice were crossed with the Has2flox/flox 
line  to  generate  FSP­1–Cre+/Has2flox/flox  (Has2FKO/FKO)  mice. 
These mice are viable and demonstrate no overt phenotype 
in the unchallenged state. We challenged Has2FKO/FKO mice 
with bleomycin and found a substantial inhibition in the accu­
mulation of both HA (Fig. 3 A) and collagen in lung tissue after 
injury (Fig. 3, B and C). In addition, there was also a decrease 
in the accumulation of myofibroblasts as assessed by ASMA 
staining of lung tissues (Fig. 3 D). Thus, two different fibro­
blast driver lines show that HAS2 expression by mesenchymal 
cells is critical for the development of pulmonary fibrosis and 
myofibroblast accumulation after tissue injury. These gain and 
loss of function interventions support a fundamental role for 
HAS2 in the development of pulmonary fibrosis.
HAS2 expression in myofibroblasts promotes  
an invasive phenotype
We investigated the hypothesis that fibrotic fibroblasts acquire 
an invasive phenotype that is essential for severe fibrogenesis 
Figure 3.  Targeted deletion of HAS2 in mesenchymal cells inhibits lung fibrosis and myofibroblast accumulation. (A) HA content in lung tissue  
from Has2FKO/FKO and Has2flox/+ mice on day 14 after bleomycin treatment (n = 3–8 per group; *, P < 0.05). (B) Lung tissues from Has2FKO/FKO and control Has2flox/+ 
mice on days 0, 14, and 21 after bleomycin treatment were collected and assayed for collagen content using the hydroxyproline method (n = 4–11 per group;  
*, P < 0.05). (A and B) Error bars indicate mean ± SEM. (C) Lung sections of Has2FKO/FKO and Has2flox/+ mice on days 0 and 14 after bleomycin instillation were 
stained using Masson’s trichrome method and counterstained with hematoxylin (n = 8 in each group). (D) Double staining of HA and ASMA in bleomycin-treated  
Has2FKO/FKO and control Has2flox/+ mouse lung sections on days 0 and 14 after bleomycin instillation. The experiments were performed three times. Bars, 200 µm.JEM Vol. 208, No. 7 
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found a marked reduction in invasive capacity (Fig. 4, F and G). 
These gain and loss of function interventions support a fun­
damental role for HAS2 in the development of an invasive 
myofibroblast phenotype.
Deficiency of CD44 inhibits the progression of pulmonary 
fibrosis and regulates fibroblast/myofibroblast invasion  
of extracellular matrix
The cell surface adhesion molecule CD44 is a HA receptor, 
and macrophage CD44 is important for clearing HA frag­
ments from injured lung tissue (Miyake et al., 1990; Teder 
et al., 2002). We found that CD44 was up­regulated after 
bleomycin­induced lung injury (Fig. 5, A and B) and to a 
greater extent in ASMA­HAS2 transgenic mice (Fig. 5 B). We 
evaluated the role of CD44 in mediating the fibrogenic re­
sponse in several ways. CD44­null mice did not show signifi­
cant protection from the development of pulmonary fibrosis 
(Fig. 5, C and D), but the effect was more pronounced when 
the ASMA­HAS2 transgenic mice were bred with the CD44­
null mice (Fig. 5 E).  We then administered systemic anti­CD44 
blocking antibodies or an isotype­matched control at the time 
of lung injury. We found that lung collagen accumulation was 
significantly prevented in the ASMA­HAS2 transgenic mice 
in the presence of anti­CD44 antibodies (Fig. 5 F). To deter­
mine whether blocking CD44 could be of therapeutic bene­
fit, we treated ASMA­HAS2 transgenic mice with systemic 
anti­CD44 antibodies or isotype­matched control on days 7, 
14, and 21 after the bleomycin treatment and analyzed colla­
gen content at day 28. Collagen content was significantly re­
duced in the presence of CD44 inhibition (Fig. 5, G and H).
To determine the role of CD44 in fibroblast invasion, we 
examined  the  invasive  capacity  of  fibroblasts  isolated  from 
CD44­null mice after bleomycin treatment and found impaired 
invasive capacity (Fig. 5 I). Similar results were found from fibro­
blasts isolated from ASMA­HAS2+/CD44/ mice relative   
to control mice (Fig. 5 J). Furthermore, treating fibroblasts iso­
lated from bleomycin­challenged WT C57BL/6J mice with 
anti­CD44 antibodies blunted fibroblast invasion (Fig. 5 K).
HAS2 and CD44 regulate human IPF fibroblast invasion
To determine whether these data obtained from mouse mod­
els of fibrosis are relevant to human lung fibrosis, we isolated 
primary lung fibroblasts from patients with IPF and analyzed 
their invasive capacity. We found a striking increase in the in­
vasive capacity of IPF fibroblasts compared with fibroblasts 
isolated from normal lung tissue (Fig. 6, A and B). These data 
suggest that fibroblasts from patients with progressive pulmo­
nary fibrosis acquire an invasive phenotype, as previously de­
scribed (Thannickal et al., 2003). Interestingly, HAS2 mRNA 
expression was increased in IPF fibroblasts that invaded Matri­
gel (Fig. 6 C). The effect of HAS2 on human lung fibroblast 
invasion was then investigated by knocking down gene ex­
pression using small interfering RNA (siRNA) in primary 
cells. We found that HAS2 suppression dramatically decreased 
constitutive HA production (Fig. 6 D and Fig. S4) and markedly 
inhibited the capacity to invade matrix (Fig. 6, D and E). We then 
the ability to form cell surface coats and exclude exogenous 
particles (Fig. 4, C and D). Importantly, they were severely 
deficient in HA production (Fig. 4 E). We examined the abil­
ity of conditional Has2­null fibroblasts to invade Matrigel and 
Figure 4.  Fibroblast invasive capacity is dependent on HAS2.  
(A) The spontaneous Matrigel-invading capacity of fibroblasts from bleo-
mycin-treated (10 d) and saline-treated ASMA-HAS2+ and littermate con-
trol mice lungs was determined. Data are shown as the index of invasion 
value of the fibroblasts with or without bleomycin treatment over litter-
mate control fibroblasts without bleomycin challenge (n = 4 per group;  
*, P < 0.05). (B) mRNA relative levels of HAS2 in invasive and noninvasive 
fibroblasts isolated from bleomycin-treated (11 d) WT mouse lungs were 
determined using real-time PCR (n = 5; *, P < 0.05). (C) Phase-contrast 
photomicrographs of the pericellular matrices (HA coat) in Has2CKO/CKO 
fibroblasts compared with those in Has2flox/+ fibroblasts. Bar, 50 µm.  
(A–C) Experiments were performed three times. (D) Relative thickness of 
HA coat was calculated in 20 randomly selected cells using ImageJ (n = 
10; ***, P < 0.001). Data represent one of two independent experiments. 
(E) HA content in cultured media of Has2flox/+ and Has2CKO/CKO fibroblasts 
was measured using the HA-ELISA assay (n = 3; **, P < 0.01). The experi-
ments were performed three times. (F) Comparison of the invasive capac-
ity between Has2flox/+ and Has2CKO/CKO fibroblasts. Data are shown as the 
invasion index of Has2CKO/CKO fibroblasts over Has2flox/+ fibroblasts. They 
are representative of three independent experiments (n = 3; **, P < 0.01). 
(G) Comparison of the invasive capacity between fibroblasts from bleomy-
cin-treated Has2flox/+ and Has2FKO/FKO mice. Data are shown as the invasion 
index of Has2FKO/FKO fibroblasts over Has2flox/+ fibroblasts (n = 3; *, P < 0.05). 
The experiments were performed three times. (A, B, and D–G) Error bars 
indicate mean ± SEM.1464 Matrix regulates fibroblast invasion | Li et al.
HAS2 regulates fibroblast invasion by modulating CD44  
and matrix metalloproteinase (MMP) expression levels
To gain additional insights into the potential mechanisms for 
the enhanced invasive phenotype of fibroblasts from both a 
mouse model of severe fibrosis as well as from patients with 
treated IPF fibroblasts with anti­CD44 antibodies that recognize 
human CD44 and demonstrated a marked reduction in inva­
sive capacity (Fig. 6 F). Collectively, these data suggest that 
unrelenting pulmonary fibrosis is dependent on a matrix­ 
invading fibroblast phenotype regulated by HAS2 and CD44.
Figure 5.  CD44 regulates lung fibrosis and fibroblast invasive capacity. (A) Western blot analysis of CD44 expression using KM114 anti-CD44 
antibodies in WT lung tissues at the indicated times after bleomycin treatment. Samples loaded at each time point were the mixture of equal amounts 
of three samples collected per time point. -Actin was used as a loading control. CD44 standard form (82.0 kD) is indicated. (B) Immunoblot of CD44 
in ASMA-HAS2+ (+) and control () mouse lung tissues on days 0 and 7 after bleomycin treatment. (C) Lung tissues from CD44-null and WT mice on 
day 21 after bleomycin treatment were collected and assayed for collagen content using the hydroxyproline method (n = 14–17 per group). (A–C) The 
experiments were performed three times. (D) Lung sections of WT and CD44-null mice on day 21 after bleomycin instillation were stained using Mas-
son’s trichrome method. Representative images of the staining are shown (n = 5–6). The experiment was repeated twice. (E) Hydroxyproline content 
on days 0 and 21 after bleomycin treatment was analyzed in ASMA-HAS2+/CD44+/+ and ASMA-HAS2+/CD44/ mice (n = 7–8 per group; **, P < 0.01). 
(F) Neutralizing anti-CD44 antibodies were instilled i.p. 12 h before and 5 d after bleomycin treatment in ASMA-HAS2+ mice. Lungs were analyzed for 
hydroxyproline content on day 14 after bleomycin instillation (n = 5–8 per group; *, P < 0.05). (G) Anti-CD44 neutralizing antibodies were instilled i.p. 
on days 7, 14, and 21 after bleomycin treatment, and lungs were analyzed for hydroxyproline content at day 28 (n = 6–9 per group; ***, P < 0.001). 
(E–G) The experiments were performed three times. (H) Lung sections of the mice described in G were stained using Masson’s trichrome method. Rep-
resentative images of the staining are shown. (I) The spontaneous Matrigel-invading capacity of fibroblasts from bleomycin-treated (7 and 11 d) and 
saline-treated WT C57BL/6J and CD44-null mouse lungs was determined. Data are shown as the index of invasion value of the fibroblasts with or 
without bleomycin treatment over WT fibroblasts without bleomycin challenge (n = 4 per group; *, P < 0.05). (J) Invasive capacity of mesenchymal 
cells from ASMA-HAS2, ASMA-HAS2+, ASMA-HAS2/CD44/, and ASMA-HAS2+/CD44/ mouse lungs with or without bleomycin challenge was 
compared. Data are shown as the index of invasion value of the fibroblasts with or without bleomycin treatment over ASMA-HAS2 fibroblasts with-
out bleomycin challenge (n = 4 per group; *, P < 0.05; ***, P < 0.001). (K) Invasion of bleomycin-treated WT mouse lung fibroblasts with (anti-CD44)  
or without (IgG) neutralizing CD44 antibody incubation (n = 4 per group; **, P < 0.01). (I–K) The experiments were repeated three times.  
(C, E–G, and I–K) Error bars indicate mean ± SEM. Bars, 200 µm.JEM Vol. 208, No. 7 
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(Fig. 7, D and E; and Fig. S5). Finally, we cultured fibroblasts 
from ASMA­HAS2+ and WT mice in Matrigel and found 
that fibroblasts from ASMA­HAS2+ fibroblasts secreted more 
pro­MMP9 than fibroblasts from control ASMA­HAS2 mice 
(Fig. 7 F) that were enzymatically active (Fig. 7, G and H). 
Collectively, these data suggest that HA–CD44 interactions 
and up­regulation of HAS2 in the context of matrix induce 
the activation of a gene program that promotes an invasive   
fibroblast phenotype and severe fibrosis.
DISCUSSION
The mechanisms that control severe and progressive tissue   
fibrogenesis are incompletely understood. In this study, we 
interrogated the role of HA expression by myofibroblasts in 
the pathogenesis of pulmonary fibrosis. We generated a novel 
model of severe and progressive fibrosis after lung injury by 
targeting Has2 expression to ASMA­expressing cells. Intersti­
tial overexpression of HAS2 by myofibroblasts produced fatal 
lung fibrosis, whereas conditional knockout of HAS2 in mes­
enchymal cells thwarted both the development of lung fibro­
sis and emergence of myofibroblasts. We provide several lines 
of evidence in vivo supporting the concept that HA and its 
cognate cell surface receptor CD44 regulate lung fibrosis after 
lung  injury.  CD44  contributed  to  the  progressive  fibrotic 
phenotype because either crossing the ASMA­HAS2 transgenic 
mice with CD44 deficient mice or treatment with a 
blocking antibody to CD44 reduced lung fibrosis.
IPF, we examined patterns of gene expression induced during 
invasion. Fibroblasts are heterogenous and only a subset are 
invasive, so we reasoned that clues to the mechanisms regulat­
ing invasion could be gained by studying fibroblasts after   
invasion. Fibroblasts from ASMA­HAS2+ mice were layered 
onto Matrigel­coated wells, RNA from the fibroblasts that 
invaded the matrix through to the underlying filter was iso­
lated, and quantitative RT­PCR (qRT­PCR) array analysis 
was  performed.  Control  samples  were  the  fibroblasts  that 
penetrated the filter in the absence of Matrigel. In addition to 
the up­regulation of HAS2 (Fig. 4 B) and CD44 (Fig. 7 B) 
expression in invasive cells, we identified a marked up­regulation 
in the expression of MMPs (MMP9, ­12, and ­14; Fig. 7 A), 
which promote fibroblast migration and invasion (Stamenkovic, 
2000; Kessenbrock et al., 2010), down­regulation of tissue in­
hibitor of metalloproteinase (TIMP; TIMP3; Fig. 7 A), which 
has been shown to inhibit cell invasion of matrix (Baker et al., 
1998; Kessenbrock et al., 2010), and ADAMTS1 (Fig. 7 A), 
which has been reported to play a role in renal fibrosis (Mittaz 
et al., 2005). Similar patterns of gene expression were also 
observed in invasive IPF fibroblasts, including an up­regulation 
in MMP9 (Fig. 7 C). We then investigated whether the   
alterations in gene expression were a direct consequence of 
Has2. Interestingly, we found that HAS2 knockdown directly 
suppressed CD44 and MMP9 gene and protein expression 
Figure 6.  HAS2 and CD44 are required for human lung 
fibroblast invasion. (A) Invasive capacity of human fibroblasts 
from normal subjects (NHF; n = 5) and IPF patients (n = 9). 
Results are for five separate experiments and are expressed as 
the invasion index of the IPF fibroblasts over the normal fibro-
blasts (*, P < 0.05). (B) Representative images of invasive IPF 
fibroblasts and normal fibroblasts. (C) Relative HAS2 mRNA 
levels of invasive and noninvasive IPF fibroblasts were deter-
mined using real-time PCR (n = 7; *, P < 0.05). The experiments 
were repeated two times. (D) 48 h after transfection with HAS2 
siRNA (HAS2 si) and control siRNA (control si), photomicro-
graphs demonstrating the effects of HAS2 si on fibroblast cel-
lular surface HA, photomicrographs demonstrating the effects 
of HAS2 si on HA coat formation, and images of invasive HAS2 
siRNA– and control siRNA–transfected fibroblasts are shown. 
(E) 48 h after HAS2 and control siRNA transfection, equal num-
bers of fibroblasts from normal donors (n = 2) and IPF patients 
(n = 3) were loaded into invasion chambers and incubated for 
another 24 h. Invasive cells were counted. Data are shown as 
the invasion index of HAS2 siRNA–transfected normal, IPF  
fibroblasts and control siRNA–transfected IPF fibroblasts over 
control siRNA–transfected normal fibroblasts (**, P < 0.01).  
(F) After 20 min of incubation with anti-CD44 neutralizing or 
isotype-matched control IgG antibody, fibroblasts from normal 
donors (n = 3) and IPF patients (n = 6) were subjected to the 
invasion assay. Data are depicted as the invasion index  
(**, P < 0.01). (D–F) The experiments were repeated three  
times. (A, C, E, and F) Error bars indicate mean ± SEM. Bars:  
(B and D [top and bottom]) 200 µm; (D, middle) 100 µm.1466 Matrix regulates fibroblast invasion | Li et al.
We provide in vivo evidence demonstrating that myo­
fibroblasts directly contribute to exaggerated fibrosis. There are 
multiple studies suggesting that expression of ASMA is a hall­
mark of fibroblastic foci in IPF (Hinz et al., 2007; Larsson   
et al., 2008), and myofibroblast accumulation has been dem­
onstrated in experimental lung fibrosis (Horowitz et al., 2007; 
Kim et al., 2009). Although the source of myofibroblasts in 
the fibrotic lung have been suggested from a variety of sources 
including resident fibroblasts (Hinz et al., 2007), epithelial 
cells (Kim et al., 2009), or bone marrow (Epperly et al., 2003; 
Hashimoto et al., 2004), the contribution of myofibroblasts to 
fibrogenesis is well accepted. It should be noted that ASMA–
expressing cells also include endothelial cells (Lu et al., 2004) 
and bone marrow stroma (Peled et al., 1991), although the 
expression in these cells may require activation by TGF­ or 
tissue injury (Ando et al., 1999).
A salient feature of this progressive fibrotic phenotype was 
the acquired ability of fibroblasts/myofibroblasts to invade   
extracellular matrix. We confirmed previous observations that 
fibroblasts from patients with IPF show an invasive property 
when  compared  with  fibroblasts  from  normal  individuals 
(White et al., 2003a). IPF biopsies often show areas of de­
nuded basement membrane (White et al., 2003a), possibly re­
sulting from alveolar epithelial cell apoptosis (Kuwano et al., 
2002). The destruction of basement membrane was also ob­
served in experimental lung injury and fibrosis (Fukuda et al., 
1985; Vaccaro et al., 1985). Similar to cancer cells, fibrotic 
myofibroblasts acquire the ability to invade damaged base­
ment membrane underneath the epithelium. Previous studies 
suggest that integrins (White et al., 2003b) and urokinase­
type plasminogen activator cellular receptor (Zhu et al., 2009) 
may have a role in fibroblast invasion during lung fibrogenesis. 
We demonstrated that the invasive phenotype required both 
HAS2 and CD44 because targeting either by multiple ap­
proaches inhibited tissue invasion. The invasive phenotype of 
IPF fibroblasts was abrogated by down­regulating Has2 ex­
pression. Finally, we could inhibit invasion of IPF fibroblasts 
with anti­CD44 antibodies. Fibroblasts from IPF patients are 
known to exhibit heterogeneous biological properties (Jordana 
et al., 1988). We found that the invasive phenotype emerges 
through contact with the matrix. Normal lung fibroblasts do 
not invade the matrix, and only a subset of ASMA­HAS2 
transgenic and IPF fibroblasts are invasive. Importantly, we are 
the first to show that targeting invasion is effective in amelio­
rating pulmonary fibrosis. Collectively, these data identify a 
previously  unrecognized  pathway  by  which  fibrotic  fibro­
blasts acquire an invasive phenotype analogous to metastatic 
cancer cells.
We  propose  that  progressive  lung  fibrosis  requires  the 
generation of an activated myofibroblast phenotype that is 
characterized by HAS2 expression and the ability to invade 
basement membrane at least partly through CD44 and co­
ordinated expression of MMPs and inhibitors of MMP func­
tions. We provide data in support of a previously unsuspected 
role for myofibroblast production of HA as a downstream 
mediator of persistent lung fibrosis by promoting the generation 
Figure 7.  HAS2 promotes fibroblast invasion by regulating CD44 
and MMP expression and function. (A and B) RNA was extracted from 
invasive ASMA-HAS2+ fibroblasts, and 84 genes were analyzed by using a 
specialized qRT-PCR array for extracellular matrix synthesizing and de-
grading enzymes. RNAs from the fibroblasts that penetrated the filter in 
the absence of Matrigel were used as control. Representative genes up- or 
down-regulated in invasive ASMA-HAS2+ fibroblasts are shown (n = 5;  
*, P < 0.05; **, P < 0.01). (B) CD44 mRNA expression in invasive fibroblasts 
versus noninvasive fibroblasts from bleomycin-treated ASMA-HAS2+ 
lungs (n = 5; *, P = 0.05). (C) MMP9 mRNA expression in invasive IPF  
fibroblasts was compared with IPF fibroblasts that penetrated the filters in 
the absence of Matrigel by using real-time PCR (n = 5). The experiments 
were performed twice. (D) CD44 mRNA expression in HAS2 siRNA (HAS2 
si)–transfected fibroblasts and control siRNA (control si) transfectants 
was determined using a microarray assay. The horizontal bars indicate the 
median expression values (n = 4; *, P < 0.05). (E) 48 h after HAS2 siRNA 
and control siRNA transfection, fibroblasts were cultured on Matrigel for 
an additional 6 h. mRNA was then extracted, and MMP9 mRNA expres-
sion was measured using real-time PCR. Data shown represent one of two 
separate experiments. (F) Fibroblasts from ASMA-HAS2 and ASMA-
HAS2+ mice were cultured on Matrigel for 96 h, and pro-MMP9 protein in 
the media was measured using a pro-MMP9 ELISA kit (n = 3–7 per group; 
*, P < 0.05). The experiments were performed three times. (G) The media 
described in F was concentrated 10× using Microsep centrifugal devices. 
Equal amounts of protein were subjected to gelatin zymography for 
MMP9 activity. A representative image is shown. The experiments were 
repeated two times. (H) Quantification analysis of gelatin zymography for 
MMP9 activity results by using ImageJ software (n = 4–5 per group;  
*, P < 0.05). (A–F and H) Error bars indicate mean ± SEM.JEM Vol. 208, No. 7 
Article
1467
requires the generation of an invasive myofibroblast pheno­
type that requires TGF­, where HAS2 and CD44 are critical 
downstream components of TGF­–induced fibrosis. Collec­
tively, genes that are dysregulated in Has2­overexpressing 
myofibroblasts are important for cellular invasion on multiple 
fronts and may indicate another link between severe fibrosis 
and metastatic cancers.
Myofibroblast CD44 coupled with Has2 overexpression 
promotes the emergence of a gene program essential for tissue 
invasion. A novel aspect of this study is the observation that 
the emergence of the invasive phenotype appears to require 
contact with the matrix. The finding that coordinated gene 
expression with up­regulation of matrix­degrading enzymes 
and down­regulation of inhibitors of these enzymes occurs in 
both mouse and man suggests that this approach could be 
used to identify therapeutic targets. The proof of principle 
experiments that CD44 antibodies attenuated lung fibrosis in 
mice in vivo encourages further investigations of this pathway. 
Understanding the genomic and translational programs lead­
ing to an invasive myofibroblast phenotype and elucidating 
the proximal signaling pathways that mediate HA and CD44 
effects on fibroblast invasion could represent novel approaches 
to the treatment of disorders characterized by progressive 
tissue fibrosis.
MATERIALS AND METHODS
Mice. ASMA–human  HAS2  transgenic  mice  (ASMA­HAS2+)  were  de­
scribed previously (Chai et al., 2005). The conditional Has2­null allele was 
generated using the Cre/loxP system (Matsumoto et al., 2009). HAS2 pro­
tein is a multipass transmembrane protein. This conditional allele was de­
signed in such a way that exon 2, which contains the start codon as well as 
two N­terminal transmembrane domains crucial for the insertion of HAS2 
protein into the plasma membrane, is deleted upon Cre­mediated recombi­
nation, and thereby no HAS2 protein is produced. Has2flox/+ designates the 
intact conditional allele before recombination. The Cre recombinase–expressing 
mice under the control of the collagen12 promoter and enhancer (Col12­
iCre+) were provided by P. Angel (Deutsches Krebsforschungszentrum, 
Heidelberg, Germany; Florin et al., 2004). For the conditional deletion of HAS2, 
two chimeras of Has2flox/+ mice were crossbred to obtain Has2flox/flox homo­
zygous mice. Has2flox/flox homozygous mice were then crossed with Col12­
iCre+ mice to generate Col12-iCre+/Has2flox/+. Further breeding with 
Has2flox/flox homozygous mice resulted in four genotypes in the offspring,   
including the conditional knockout mutant for Has2 (Col12-iCre+/Has2/; 
termed Has2CKO/CKO). Mice expressing Cre under the control of the FSP­1 
(also called S100A4) promoter (FSP­1–Cre) were provided by T. Blackwell 
(Vanderbilt University, Nashville, TN; Lawson et al., 2005; Tanjore et al., 
2009). CD44/ mice were provided by T.W. Mak (Amgen Research Institute, 
Toronto, Ontario, Canada; Schmits et al., 1997). We crossbred ASMA­HAS2+ 
with CD44/ to generate chimeras of ASMA­HAS2+/CD44+/, and we 
then backcrossed the two chimeras to get ASMA­HAS2+/CD44/ mice. 
C57BL/6J mice were obtained from The Jackson Laboratory. All mice were 
housed in a pathogen­free facility at Duke University, and all animal experi­
ments were approved by the Institutional Animal Care and Use Committee 
at Duke University.
Fibroblast isolation and culture. Primary fibroblasts were derived from 
mouse lungs as described previously (Tager et al., 2008; Jiang et al., 2010). 
The cells were used from three to six generations. Human lung fibroblasts 
were isolated from surgical lung biopsies or lung transplant explants obtained 
from patients with IPF. Normal lung fibroblasts were obtained from discarded 
portions  of  normal  transplant  donor  lung  tissue. The  specimens  were   
of an invasive fibroblast phenotype. These data suggest that 
HAS2 plays a key role in promoting fibrogenesis in several 
ways. First, HAS2 overexpression increased CD44 expres­
sion and HA production. Second, HAS2 overexpression   
promoted activation of a gene program that facilitates emer­
gence of an invasive phenotype. We identified an up­regulation 
in the expression of MMPs and down­regulation of tissue in­
hibitors of metalloproteinase. The resultant imbalance in the 
ratio of MMP/TIMP expression in fibrotic fibroblasts pro­
vides a mechanism to promote tissue invasion. MMP­12 has 
been shown to contribute to pulmonary fibrosis in two dif­
ferent model systems, although the precise mechanism is un­
known (Kang et al., 2007; Madala et al., 2010). The loss of 
Timp­3 leads to the development of kidney fibrosis (Kassiri 
et al., 2009). In addition, mice deficient in Timp3 have in­
creased expression of MMP1a and enhanced pulmonary fi­
brosis after bleomycin treatment (Gill et al., 2010). We also 
observed the down­regulation of a disintegrin­like and me­
tallopeptidase (ADAMS) with thrombospondin type 1 motif 1 
(ADAMTS1). ADAMTS1 is a procollagen N­proteinase that 
processes several types of procollagen proteins to mature 
collagen and is also important for collagen fibril assembly in 
the extracellular matrix. ADAMTS1 has not been explored in 
lung fibrosis, but it has been reported to play a role in renal   
fibrosis (Shindo et al., 2000; Mittaz et al., 2005). Deletion of 
Adamts1 increased interstitial fibrosis in the kidney (Shindo 
et al., 2000). Given the multiple roles in tumor microenviron­
ment, it is anticipated that MMPs (Kessenbrock et al., 2010), 
ADAMS (Murphy, 2008), and cell adhesion molecules co­
ordinate with extracellular components such as HA and CD44 
to regulate fibrotic fibroblast invasion. Although our experi­
ments have focused on HAS2, we cannot exclude roles for 
HAS1 and HAS3.
Further studies will be required to determine whether the 
development of an invasive fibrotic phenotype requires growth 
factors such as TGF­ or PDGF (platelet­derived growth 
factor). TGF­ has been recognized as a critical regulator of 
tissue fibrosis in general, and numerous studies have provided 
strong support in favor of a nonredundant role in lung fibrosis 
in particular (Sime et al., 1997; Munger et al., 1999). TGF­ 
has been shown to be required for the development of bleo­
mycin­induced pulmonary fibrosis, is a potent stimulator of 
HA production, and has been shown to promote the transi­
tion of resident fibroblasts to myofibroblasts in vitro (Webber 
et al., 2009). The downstream effector pathways following 
TGF­ activation leading to unrelenting tissue fibrosis have 
not  been  fully  elucidated.  Numerous  studies  suggest  that 
TGF­  regulates  the  expression  of  MMP/TIMP  balance 
(Kim et al., 2004; Kang et al., 2007). Furthermore, CD44 has 
been shown to interact with MMP­9 and promote tumor 
metastasis by serving as a cell surface docking receptor for pro­
teolytically active MMP­9 that cleaves latent TGF­ to release 
active TGF­ during tumor metastasis (Yu and Stamenkovic, 
2000). CD44 has been shown to directly interact with MMP­14 
(MT1­MMP) to promote tumor cell invasion (Marrero­Diaz 
et al., 2009). We anticipate that progressive lung fibrosis   1468 Matrix regulates fibroblast invasion | Li et al.
total RNA was purified using RNAqueous­4PCR kit (Invitrogen) and was 
reversed to cDNA using SuperScript II RNase H RT kit (Invitrogen) ac­
cording to the manufacturer’s instructions. HAS2 gene levels in the resul­
tant cDNAs were examined using the ABI Prism 7500 Detection system 
(Applied Biosystems) with SYBR green as fluorescent dye enabling real­
time detection of PCR products according to the manufacturer’s protocol 
(Power SYBR green PCR Master Mix; Applied Biosystems). The relative 
expression levels of the gene were determined against GAPDH levels in 
the samples. The same method was used to measure the relative mRNA 
levels of mouse HAS2 and human HAS2 genes in ASMA­HAS2+ mice and 
transgene­negative littermate controls with or without bleomycin treatment 
and was used to measure HAS2, MMP9, MMP12, and MMP14 mRNA 
levels in mouse and human lung fibroblasts. The following primers were 
used: human HAS2 (GenBank/EMBL/DDBJ accession no. NM_005328) 
forward,  5­TCGCAACACGTAACGCAAT­3;  human  HAS2  reverse,   
5­ACTTCTCTTTTTCCACCCCATTT­3; human MMP9 (GenBank 
accession no. NM_004994) forward, 5­CCCACTGCTGGCCCTTCTA­3;   
human MMP9 reverse, 5­TCACGTTGCAGGCATCGT; human MMP12 
(GenBank accession no. NM_002426) forward, 5­TGCACGCACCTCGA­
TGTG­3; human MMP12 reverse, 5­GGCCCCCCTGGCATT­3; human 
MMP14 (GenBank accession no. NM_004995) forward, 5­CGAGAG­
GAAGGATGGCAAATT­3;  human  MMP14  reverse,  5­AGGGAC­
GCCTCATCAAACAC­3;  human  GAPDH  (NM_002046)  forward,   
5­CCCATGTTCGTCATGGGTGT­3; human GAPDH reverse, 5­TGGT­
CATGAGTCCTTCCACGATA­3;  mouse  HAS2  (GenBank  accession  no. 
NM_008216) forward, 5­ACGACGACCTTTACATGATGGA­3; mouse 
HAS2 reverse, 5­GATGTACGTGGCCGATTTGCT­3; mouse GAPDH 
forward,  5­ATCATCTCCGCCCCTTCTG­3;  and  mouse  GAPDH  
reverse, 5­GGTCATGAGCCCTTCCACAAC­3.
Microarray assay. At 48 h after transfection, RNA from HAS2 siRNA– 
and control siRNA–transfected human lung fibroblasts was purified using 
the RNAqueous­4PCR kit. Affymetrix microarray (genechip U133A 2.0) 
was used for comparing CD44 gene expression level in the HAS2 knock­
down cells with that in the control cells.
qRT-PCR array assay. Fibroblasts from bleomycin­treated ASMA­HAS2+ 
mice were loaded onto 6­well Matrigel chambers or 6­well insert chambers 
without Matrigel (BD) and cultured in a CO2 incubator for 48 h. Matrigel 
matrix and noninvading cells on the upper surface of the filter were removed 
by wiping with a cotton swab, the polycarbonate filters with the invaded cells 
or migrated cells were washed once with PBS, and RNA was isolated from 
the cells using the RNAqueous­4PCR kit. RT was performed using the RT2 
First Strand cDNA Synthesis kit (QIAGEN), and 84 genes were assessed by 
RT­PCR using the Mouse Extracellular Matrix and Adhesion Molecules   
array (RT2 Profiler PCR Array PAMM­013; QIAGEN) according to the 
manufacturer’s instructions using the ABI Prism 7500 Detection system. For 
analysis, the expression level for each gene of interest (GOI) was calculated as 
2­Ct followed by normalization to GAPDH (HKG), using the formula   
2  (Ct GOI  Ct HKG). Ultimately, the fold change in normalized gene 
expression was calculated by comparing values from the invaded fibroblasts 
through Matrigel (with invasion) with the migrated fibroblasts through filter 
without Matrigel (without invasion) according to the following formula:   
2­Ct with invasion/2­Ct without invasion. Values were calculated for replicates 
of five independent experiments.
HA pericellular coat determination. Fibroblasts isolated from Has2flox/+, 
Has2CKO/CKO mouse lungs, and fibroblasts from human lung tissues were in­
cubated at 104 cells/well of a 6­well plate for 24 h in 10% FBS­DME and 
were then overlaid with 107 erythrocytes. The erythrocytes were allowed to 
settle for 15 min at room temperature, and the cells were observed with an 
inverted microscope with a phase contrast at 200× magnification with a 
camera (AxioCam MRC5; Carl Zeiss). The size of the pericellular coat was 
defined by the subtraction between the area excluding erythrocytes and cell 
area by using the ImageJ program (National Institutes of Health).
obtained under the auspices of Institutional Review Board–approved proto­
cols. The tissues were minced and cultured in DME supplemented with 15% 
FBS, 100 U/ml penicillin, 100 µg/ml streptomycin, 5 µg/ml gentamicin, 
and 0.25 µg/ml amphotericin B. The cells of passage 5–7 were used for inva­
sion assays, siRNA interference assays, and HA coat and HA amount mea­
surements. The diagnosis of IPF was arrived at by standard accepted American 
Thoracic Society recommendations (ATS/ERS, 2000). All experiments were 
approved by the Duke University Institutional Review Board and in accor­
dance with the guidelines outlined by the board.
Bleomycin  administration  and  BAL.  Bleomycin  was  injected  intra­
tracheally at either a dose of 2.5 U/kg body weight for analysis of the early 
inflammatory response or 1.75 U/kg body weight for analysis of the late 
fibrotic response. Anesthesia was provided with a mixture of ketamine of 
100 mg/kg (Fort Dodge) and xylazine of 10 mg/kg (Shenandoah). At designated 
time points after bleomycin injection, mice were euthanized by ketamine 
mixture injection, and lungs were harvested for RNA preparation, protein 
isolation, or fibroblast isolation. For BAL, the trachea was lavaged three times 
with 0.8 ml sterile saline at room temperature. Samples were centrifuged at 
1,500 rpm for 5 min, and the supernatant was collected and stored at 80°C 
until used. The cell­free supernatants were then analyzed for HA and chemo­
kine KC concentrations by specific ELISA. The cell pellets were resolved in 
1 ml sterile saline, and the cells were counted with a hemocytometer. Ap­
proximately 40,000 cells from each specimen were loaded onto slides. These 
slides were stained using a Protocol Hema 3 stain set (Thermo Fisher Scien­
tific) and reviewed under light microscopy for white blood cell differential.
HA quantification. BALF and lung tissues were collected at different times 
after bleomycin treatment. Lung tissues were excised, weighed, and homoge­
nized as described previously (Teder et al., 2002). After centrifugation, the 
HA content in the tissue supernatants and in BALF was measured using the 
HA­ELISA (Teder et al., 2002). The HA content in cultured media of human 
lung fibroblasts was quantified using the same ELISA method.
Histology, ASMA,  and  HA  immunohistochemistry. Three to eight 
mice in each group were sacrificed at various times after bleomycin treat­
ment under anesthesia. The trachea was cannulated, and the lungs were in­
flated with 1 ml of 10% formalin. The tissues were then fixed overnight, 
embedded in paraffin, and sectioned for staining with hematoxylin and eosin 
or Masson’s trichrome. Paraffin­embedded lung samples were also analyzed 
for HA localization. After being dewaxed and rehydrated, tissues were incu­
bated with 4 µg/ml biotin­labeled HA­binding protein (HABP; Associates of 
Cape Cod, Inc.) for 1 h and then incubated and developed using a VECTA­
STAIN Elite ABC kit (Vector Laboratories). The specificity of the staining 
was determined by preincubating tissue samples with 10 U/ml streptomyces 
hyaluronidase for 2 h at room temperature. For ASMA staining, tissue sec­
tions were incubated with horseradish peroxidase–conjugated anti­ASMA 
monoclonal antibody (Dako) and then incubated with the VECTASTAIN 
Elite ABC kit as described above. For HA and ASMA double staining, tissue 
sections were incubated with biotin­HABP overnight at 4°C, followed by 
incubation with Cy3­labeled anti­ASMA antibody (Sigma­Aldrich) to de­
tect ASMA and streptavidin and Alexa Fluor 488 conjugate (Invitrogen) 
to detect HA. The processed sections were mounted in Fluoromount­G   
(Immunokemi)  containing  DAPI  and  photographed  with  a  microscope 
(Axio Imager A1; Carl Zeiss).
Hydroxyproline assay. Collagen content in lung tissue from 4–17 mice per 
group was measured with the conventional hydroxyproline method (Adamson 
and Bowden, 1974). The ability of the assay to completely hydrolyze and re­
cover hydroxyproline from collagen was confirmed using samples containing 
known amounts of purified collagen.
Quantification  of  mRNA  expression. Real­time RT­PCR was used 
to quantify the relative mRNA levels of HAS2 in C57BL/6J mice with 
or without bleomycin instillation using gene­specific primers. In brief,   JEM Vol. 208, No. 7 
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Student’s t test or Wilcoxon rank­sum test with nonparametric data. Differ­
ences between multiple groups were calculated using one­way analysis of 
variance with Tukey­Kramer posttest or two­way analysis of variance with 
Bonferroni multiple comparisons. Statistic significance of survival curves was 
analyzed with the log­rank test. Statistical difference was accepted at P < 0.05. 
Prism 5.0 (GraphPad Software) or JMP5 software (SAS Institute) was used to 
perform statistical analysis.
Online supplemental material. Fig. S1 shows that ASMA­HAS2+ mice 
exhibit an increase in neutrophil recruitment after lung injury. Fig. S2 shows 
increased HA fragment accumulation in ASMA­HAS2+ mouse lungs after 
bleomycin treatment. Fig. S3 shows that targeted deletion of HAS2 in mes­
enchymal cells inhibits lung fibrosis and myofibroblast accumulation. Fig. S4 
shows that HAS2 siRNA efficiently reduces HAS2 gene expression and HA 
production in primary human lung fibroblasts. Fig. S5 shows that suppres­
sion of HAS2 decreased CD44 protein level. Online supplemental material is 
available at http://www.jem.org/cgi/content/full/jem.20102510/DC1.
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the filters were removed from the insert by a scalpel blade and were mounted 
onto glass slides. The invading cells of each sample were counted in five randomly 
selected fields of duplicate filters under a microscope at 400× magnification. The 
invasive capacity of fibroblasts from IPF patients was compared with fibroblasts 
from normal donators using the same invasion assay. CD44 effects on mouse and 
human lung fibroblasts invasion were assessed using 15 µg/ml anti­CD44 block­
ing antibodies (5F12 clone for human CD44; KM201 for mouse CD44). The 
cells were incubated with anti­CD44 or isotype­matched IgG for 20 min before 
performing the invasion assay. The effects of HAS2 expression levels on human 
lung fibroblasts’ invasion were investigated by performing the invasion assay at   
48 h after HAS2 siRNA and control siRNA transfection.
RNA interference assay. Four siRNA duplexes designed to target different 
nucleotide sequences (HAS2 si, 1530–1550; HAS2 si2, 1051–1071; HAS2 si3, 
1424–1444; and HAS2 si4, 1777–1797) of the human HAS2 gene (GenBank 
accession no. NM_005328) were obtained from QIAGEN. Subconfluent   
fibroblasts (50–60% confluent) grown in complete medium were trans­
fected separately with each one of the four siRNA duplexes or with a control 
siRNA (control si; QIAGEN) at the concentration of 100 nM using Hiper­
Fect transfection reagent (QIAGEN) according to the manufacturer’s in­
structions. The suppression efficiency of each one of the four siRNA duplexes 
was examined by measuring the HA content in the conditioned culture 
media after 48 and 72 h of transfection, HAS2 mRNA at 72 h after transfection, 
and HA coat at 48 h after transfection. The HAS2 siRNA corresponding to 
nucleotide sequences 1530–1550 of the HAS2 cDNA (5­CAGCTCGATC­
TAAGTGCCTTA­3; HAS2 si) was used for all experiments.
Western blotting. WT, ASMA­HAS2+, and littermate control lung tissues 
after bleomycin treatment were homogenized in radioimmunoprecipitation 
assay buffer. The proteins were fractionated by SDS­PAGE using gradient gel 
(4–20%; Bio­Rad Laboratories) and electroblotted onto nitrocellulose mem­
brane (Bio­Rad Laboratories). The membranes were probed with a rat 
monoclonal anti­CD44 antibody (KM114; BD) and then probed with rela­
tive second antibody. ­Actin was used as a loading control.
Administration  of  neutralizing  anti-CD44  monoclonal  antibody. 
TIB­240 hybridoma cells producing rat anti–mouse CD44 blocking anti­
body (KM201) were purchased from the American Type Culture Collection. 
The antibody was isolated using saturated ammonium sulfate method. Two 
schemes were used for the antibody administration. For the preventive pro­
tocol, KM201 or isotype control rat IgG1 (300 µg in 500 µl saline) was ad­
ministered i.p. 12 h before bleomycin challenge, and repeated injections were 
given in the same way (200 µg/500 µl saline) on day 5 after bleomycin treat­
ment. 14 d after bleomycin challenge, mouse lungs were collected, and colla­
gen content in the mouse lungs was measured using the hydroxyproline assay 
(Adamson and Bowden, 1974). For the therapeutic protocol, KM201 or iso­
type control rat IgG1 (300 µg in 500 µl saline) was administered i.p. at day 7 
after bleomycin treatment, and repeated injections were given in the same 
way at days 14 and 21 after bleomycin treatment. 28 d after bleomycin chal­
lenge, mouse lungs were collected, and collagen content in the mouse lungs 
was measured using hydroxyproline (Adamson and Bowden, 1974).
Statistical analysis. Data are expressed as the mean ± SEM where applicable. 
We assessed differences in measured variables using the unpaired two­sided 1470 Matrix regulates fibroblast invasion | Li et al.
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